BRIDGEWATER, New Jersey, November 1, 2011 /PRNewswire/ --
- Listed companies to present at Therapeutic Area Partnerships conference, Boston, November 30 - December 2
Elsevier Business Intelligence and Windhover Conferences today announced the Top Projects to Watch list. The list delivers projects and companies with high-value assets for partnership, and with the potential to create future growth through investments in deals.
This year's list includes a Top 10 in each of six therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases and inflammatory/autoimmune, plus a "hot space" category, including ophthalmology, orphan diseases, and women's health. The selected companies have been screened using a strict set of judging criteria, including unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability.
The top 10 projects chosen to present in each therapeutic area are selected by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. These independent experts include Campbell Alliance, NI Research, Healogix, Wolpert Associates, Cobbs Creek Healthcare and Herndon Associates. Senior business development executives from most of the major pharmaceutical firms as well as management from innovative biotechnology firms schedule one-on-one partnering meetings.
The complete list of all projects to date is available at http://www.windhover.com/taprojects. Each project has been hand-selected by Windhover's elite selection panel to ensure a high-quality slate of presenters.
"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, VP, Content, for Elsevier Business Intelligence's publications. "Many of the companies we selected in the past have gone on to do big deals, and we expect the same from this years' companies. 90% of the companies haven't presented at major partnering events this year."
Attendees of the Therapeutic Area Partnerships conference benefit from expert analysis of trends and opportunities in licensing and M & A dealmaking, presentations by the industry's foremost thought leaders and decision makers, actionable information on emerging, innovative companies and key licensable projects, strategies to finance and commercialize new products.
About Windhover Conferences and Elsevier Business Intelligence
Windhover Conferences is an Elsevier Business Intelligence company, the leading provider of business intelligence and analysis to senior executives in the medical device, pharmaceutical, and biotechnology industries. Publishers of The Pink Sheet, IN VIVO: The Business & Medicine Report, PharmAsia News, The Tan Sheet",Start-Up: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access, Elsevier Business Intelligence and Windhover also host a variety of industry meetings and webinars in both medical device and pharma/biotech, and produce a wide array of market research reports. For more on the companies' products and services, please visit http://www.ElsevierBI.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).